|
Use of yttrium-90 (Y90) glass microspheres (TheraSphere) as neoadjuvant to transplantation/resection in hepatocellular carcinoma: Analyses from the LEGACY study. |
|
|
Honoraria - Boston Scientific |
|
|
Consulting or Advisory Role - Boston Scientific; Genentech |
|
|
Honoraria - Boston Scientific |
Consulting or Advisory Role - Boston Scientific |
Research Funding - Boston Scientific |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boston Scientific; Bristol-Myers Squibb |
Research Funding - Varian Biopharma |
|
|
No Relationships to Disclose |